QDOSE® Software
QDOSE® Multi-purpose Voxel Dosimetry (Personalized Dosimetry in Molecular Radiotherapy). USFDA 510(k) clearance granted in August 2023.
WHY QDOSE®?
Multi-purpose Molecular Imaging Dosimetry Software
QDOSE® Multi-purpose Voxel Dosimetry (Personalized Dosimetry in Molecular Radiotherapy) provides state-of-the-art assessment of radiation absorbed dose to organs and tissues of the body from medically administered radiopharmaceuticals. This software is a complete, one-stop solution for all internal dosimetry needs with multiple parallel workflows.
Multiple time points from 2D conjugate—view imaging. Quantitative methods according to MIRD recommendations.
Multiple time points from 2D conjugate views plus quantitative SPECT/CT for data point calibration.
Multiple registered time points for quantitative SPECT/CT or PET/CT imaging.
Tool for selective internal radiation therapy using yttrium-90 microspheres for hepatocellular carcinoma. Post-treatment single-time-point yttrium-90 PET/CT or bremsstrahlung SPECT/CT. Evaluations using a Tc-99m-macroagregated albumin SPECT/CT scan.
Safety & Efficacy Dosimetry at the Same Time
QDOSE® features fully automated organ segmentation, single time-point dosimetry, and one-click hybrid dosimetry capabilities, supported by algorithms for fast data processing and an extensive radionuclide database. Integrated with IDAC-DOSE2.1, QDOSE® provides reliable estimates of organ absorbed dose and effective dose for clinical applications in nuclear medicine and molecular radiotherapy.
The Complete One-Stop Dosimetry Software
- Versatile nuclear medicine imaging interface
- DICOM and data import utility from planar scintigraphy, SPECT, PET, CT and MRI
- Rigid and deformable 3D coregistration
- Automated and semi-automated segmentation
- Automated organ coregistration
- Iterative curve fitting
- Configurable output reporting
- Organ overlap correction
Designed & Developed by Practitioners
QDOSE® was developed by ABX-CRO (Dresden, Germany) in collaboration with Quantinm AB (Stockholm, Sweden). Since its inception, QDOSE® has been MDD & MDR certified. This is a testament to its quality and compliance since 2017. QDOSE+ is the progressive evolution and enriched iteration of its predecessor, embracing enhanced features and capabilities.
THE NEXT STEP IN IRT.
QDOSE® is intended to estimate the absorbed dose to organs based on intracorporal administration of radiopharmaceuticals in patients with cancer. It is used by radiologists, nuclear medicine physicians, and medical physicists.
